All products featured on Vogue are independently selected by our editors. However, we may receive compensation from retailers and/or from purchases of products through these links. If you missed ...

Pfizer reaffirmed $10–$15 billion for business development, with focus on immunology and cardiometabolic expansion. CEO Bourla says national security concerns are central to U.S. drug ...

Pfizer's CEO said tariff uncertainty is hindering the company from making big investments in the US. Albery Bourla said there could be "tremendous investments" in R&D and manufacturing in the US ...

After years of falling Covid treatment sales, lukewarm drug launches and a fizzled out weight-loss play, Pfizer is focusing on cost-cutting and reinvesting in new drug research in hopes that it ...

Pfizer PFE shares spiked +3% in Tuesday’s trading session as the pharmaceutical giant was able to crush its Q1 earnings expectations this morning. Still, Pfizer stock has fallen 10% year to date ...

Other drugmakers are eyeing the market as well. Pfizer (NYSE: PFE) is certainly in that group. However, the company finds itself at a distinct disadvantage after it recently threw in the towel on ...

Pfizer recently said it wouldn't continue development of its weight loss candidate danuglipron, a once-daily pill, after a patient in a clinical trial experienced liver injury -- the problem ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top ...

Pfizer CEO Albert Bourla on Tuesday said uncertainty around President Donald Trump’s planned pharmaceutical tariffs is deterring the company from further investing in U.S. manufacturing and ...

New York (AFP) – Pfizer reported a dip in profits Tuesday, driven partly by lower sales of Covid-19 therapeutic drug Paxlovid, as it maintained a 2025 forecast that does not include potential ...

Pfizer stock (NYSE: PFE) has recently announced its Q1 results, reporting revenues that fell short of expectations while earnings surpassed analyst predictions. The company disclosed revenue of $ ...